Company

BioLineRx Ltd.

Headquarters: Hevel Modi'in, Israel

Founded: 2003

Employees: 38

TASE: BLRX -2.44%

Market Cap

₪177.5 Million

ILS as of July 1, 2024

US$47.1 Million

Market Cap History

BioLineRx Ltd. market capitalization over time

Evolution of BioLineRx Ltd. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of BioLineRx Ltd.

Detailed Description

BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer; and licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

Top 1-year algo backtest: +265.99%

$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Stocks & Indices

BioLineRx Ltd. has the following listings and related stock indices.


Stock: TASE: BLRX wb_incandescent

Stock: NASDAQ: BLRX wb_incandescent

Stock: FSX: YP2A wb_incandescent

Product & Services

Drug development

Key People

Philip Serlin (CEO)

Details

Headquarters:

Modi’in Technology Park

2 HaMa’ayan Street

Hevel Modi'in, 7177871

Israel

Phone: 972 8 642 9100

Fax: 972 8 642 9101